HEALTHBANKS BIOTECH CO., LTD.
🇹🇼Taiwan
Phase I, Open-Label Study of the Safety, Tolerability, and Immunogenicity PEK Fusion Protein Vaccine
Phase 1
- Conditions
- Cervical Intraepithelial Neoplasia
- Interventions
- Biological: PEK Fusion Protein Vaccine
- First Posted Date
- 2013-06-19
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- HealthBanks Biotech Co., Ltd.
- Target Recruit Count
- 15
- Registration Number
- NCT01880411
© Copyright 2025. All Rights Reserved by MedPath